Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
March 05 2024 - 4:05PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced that it will report the Company’s fourth
quarter 2023 financial results on Tuesday, March 12, 2024, after
the close of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical
company that was founded in 2018 with the mission to become a world
leader in the treatment of liver and viral diseases. Aligos’
strategy is to harness the deep expertise and decades of drug
development experience its team has in liver and viral diseases to
discover and develop potentially best in class therapeutics for
metabolic dysfunction-associated steatohepatitis (MASH) and viruses
with high unmet medical need such as chronic hepatitis B (CHB) and
coronaviruses.
Forward-Looking Statement
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered “forward-looking statements.”
Forward-looking statements are typically, but not always,
identified by the use of words such as “may,” “will,” “would,”
“believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,”
and other similar terminology indicating future results. Such
forward looking statements are subject to substantial risks and
uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, the risks and
uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the
proposed financing, risks and uncertainties inherent in the drug
development process, including Aligos’ clinical-stage of
development, the process of designing and conducting clinical
trials, the regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing drug
products, Aligos’ ability to successfully establish, protect and
defend its intellectual property, other matters that could affect
the sufficiency of Aligos’ capital resources to fund operations,
reliance on third parties for manufacturing and development
efforts, and the impact of global events and other macroeconomic
conditions on the Aligos business. For a further description of the
risks and uncertainties that could cause actual results to differ
from those anticipated in these forward-looking statements, as well
as risks relating to the business of Aligos in general, see Aligos’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 2, 2023 and its future periodic
reports to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
CompanyJordyn TaraziVice President, Investor
Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaVeronica EamesLifeSci
Communicationsveames@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2024 to May 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From May 2023 to May 2024